Viking Therapeutics (VKTX) has put its clinical pipeline in the spotlight around its Q4 2025 earnings release, with fresh trial updates on obesity candidate VK2735 and an upcoming amylin agonist ...

Viking Therapeutics, Inc. (NASDAQ:VKTX) Q4 2025 Earnings Call Transcript February 11, 2026 Viking Therapeutics, Inc. misses ...

Viking excellence shows up in a lot of ways: on the field, in the classroom, in our community. And sometimes, it travels all ...

Beyond VK2735, Viking is advancing an amylin receptor agonist as a complementary obesity mechanism, aiming to deepen its metabolic franchise. An investigational filing is expected this quarter, with ...

Phase 3 VANQUISH Trials for Subcutaneous VK2735 in Obesity Ongoing; VANQUISH-1 Enrollment Complete, VANQUISH-2 Nearing Full Enrollment -- VK2735 Maintenance Dosing Study Fully Enrolled; Data Expected ...

Once upon a time, there was a Viking king. He prayed to Thor, Odin and Freya and ruled over a land that did not yet have an ...

The Vikings will add a veteran QB in March. That QB’s track record will be the true indication of how they feel about McCarthy.

Welcome to the Viking Therapeutics Fourth Quarter and Full Year 2025 Financial Results Conference Call. [Operator Instructions] As a reminder, this conference call is being recorded today, February 11 ...

Check out the companies making the biggest moves in premarket trading: Restaurant Brands — Shares gained 1.3% following the Burger King parent's beat on the top and bottom lines . Restaurant Brands ...

Check out the companies making the biggest moves in midday trading: Crocs — Shares of the clogs manufacturer surged 21% after Crocs reported upbeat guidance for the current quarter. The company sees ...

Sam Rensch scored a career-high 30 points to elevate the Augustana men’s basketball team to a 95-83 victory over Minnesota ...

We're dialling back the clock to the 1960s - a defining decade when the bulldozers rolled, homes vanished and new landmarks changed York's skyline.